United Kingdom Mammography - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026 - 2031)

According to Mordor Intelligence, the United Kingdom mammography market size is projected to expand from USD 91.04 million in 2025 and USD 98.90 million in 2026 to USD 149.52 million by 2031, registering a CAGR of 8.63% between 2026 to 2031.

This report is Segmented by Product Type (Digital Mammography Systems, Analog Mammography Systems, Breast Tomosynthesis Systems, Other Product Types), Technology (2-D Mammography, 3-D Mammography), and End User (Hospitals, Specialty Clinics, Diagnostic Imaging Centers). The Market Forecasts are Provided in Terms of Value (USD).

United Kingdom Mammography Market Trends and Insights

Growing Incidence of Breast Cancer in the UK

Incidence continues to rise and is projected to reach one new diagnosis every eight minutes by 2040 . The demographic skew toward women older than 50 aligns directly with NHS screening eligibility, creating reliable procedure volumes that refresh the installed base of digital units. Higher cancer risk in women with dense tissue elevates demand for advanced imaging such as molecular breast imaging that complements mammography workflows. Cost estimates show breast cancer management could climb to GBP 3.6 billion by 2034, reinforcing the financial logic of early detection investments. Urban hubs with dense populations require high-throughput systems to manage growing caseloads, which strengthens the purchasing case for premium 3-D equipment that shortens recall cycles and improves detection rates. Clinical researchers at University College London are now trialing prototype dense-breast imaging technologies that will likely feed future procurement requirements.

Expansion of NHS Breast Screening Programme Coverage

The NHS strategy extends screening invitations beyond age 70 and pushes mobile services into underserved regions, instantly increasing annual mammogram demand and straining installed capacity . Performance benchmarks set a 70% coverage target, and early results from community diagnostic centers show uptake rising by nearly 50% where mobile units operate. The policy shift obliges trusts to procure additional systems or upgrade existing platforms capable of higher patient throughput. Integration with AI-based risk stratification software is becoming vital as program managers test adaptable recall intervals that tailor screening frequency to individual risk. NHS Digital data-security mandates drive procurement toward platforms offering secure cloud connections and airtight GDPR compliance.

Patient Concerns Over Cumulative Radiation Exposure

Average glandular dose ranges from 1 mGy to 10 mGy per exam, and contrast-enhanced studies can reach 11.84 mGy, prompting safety questions that lower repeat attendance. Surveys show 27% of non-attendees cite fear of pain and radiation as key deterrents. Manufacturers now market automatic exposure control systems that dynamically tailor dose by breast thickness, lowering patient anxiety and improving re-screen rates. Public-facing NHS campaigns emphasize dose transparency, quoting UNSCEAR's frequency-weighted effective dose of 0.22 mSv for standard screening to build trust.

Other drivers and restraints analyzed in the detailed report include:

1. Technological Advances in 3-D Breast Tomosynthesis
2. Rapid Adoption of AI-Enabled CAD Solutions
3. Cuts to NHS Capital Equipment Budgets

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Digital mammography accounts for 67.90% of United Kingdom mammography market share in 2025 and remains the backbone of NHS screening infrastructure. Conversion from film to digital has improved image clarity and lowered repeat rates, generating total cost savings that help offset acquisition premiums. The United Kingdom mammography market size for digital systems increased in 2026 as trusts replaced aging detectors with models that integrate wireless compression paddles and AI-ready workstations. Vendors are bundling service contracts that guarantee uptime above 99% and include remote diagnostics to reduce site visits.

Breast tomosynthesis systems post the fastest growth at 9.29% CAGR to 2031, fueled by clinical validation and regulatory endorsement. Tomosynthesis improves invasive-cancer detection by up to 65% versus 2-D and lowers recall rates by 40%. The United Kingdom mammography market size for tomosynthesis is expanding as framework agreements under NHS Supply Chain shorten tender cycles and encourage bulk procurement. Analog solutions continue to phase out, yet remain in select rural vans where power constraints and low utilization do not justify 3-D investment. Additional categories such as biopsy-guided tables and contrast-enhanced platforms are gaining niche interest as trusts pursue one-stop breast clinics.

Complete Report Scope:

• By Product Type
  • Digital Mammography Systems
  • Analog Mammography Systems
  • Breast Tomosynthesis Systems
  • Other Product Types
• By Technology
  • 2-D Mammography
  • 3-D Mammography
• By End User
  • Hospitals
  • Specialty Clinics
  • Diagnostic Imaging Centers

List of Companies Covered in this Report:

1. Hologic
2. Siemens Healthineers
3. GE HealthCare Technologies Inc.
4. Fujifilm Holdings Corp.
5. Koninklijke Philips
6. Canon
7. Carestream Health
8. Planmed
9. Metaltronica
10. IMS Giotto S.p.A.
11. General Medical Merate
12. Lunit
13. ScreenPoint Medical B.V.
14. Volpara Health Technologies Ltd.
15. iCAD Inc.
16. Sectra
17. Agfa-Gevaert
18. Densitas Inc.
19. Medtronic
20. SmartBreast Corp.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support